Meeting
2020 ASCO Virtual Scientific Program
Toxicity analysis of capecitabine/temozolomide in NETs.
Authors
Taymeyah E. Al-Toubah
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Taymeyah E. Al-Toubah , Eleonora Pelle , Mintallah Haider , Jonathan R. Strosberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4614)
DOI
10.1200/JCO.2020.38.15_suppl.4614
Abstract #
4614
Poster Bd #
222
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
First Author: Jennifer Rachel Eads
Poster
2019 ASCO Annual Meeting
Retrospective study of capecitabine and temozolomide in advanced lung neuroendocrine neoplasms.
First Author: Taymeyah E. Al-Toubah
Poster
2014 Gastrointestinal Cancers Symposium
Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
First Author: Robert Lance Fine
Poster
2023 ASCO Quality Care Symposium
Patient characteristics associated with myelosuppression among patients with extensive-stage small cell lung cancer treated with chemotherapy in the community oncology setting.
First Author: Jerome H. Goldschmidt